Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Commentary · June 04, 2024

Japan Initiates Market Authorization of Weight-Loss Drug Semaglutide Under Universal Health Coverage, With Stringent Prescription Restrictions

Diabetes, Obesity & Metabolism


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Japan initiates market authorization of weight-loss drug semaglutide under universal health coverage, but with stringent prescription restrictions
Diabetes Obes Metab 2024 May 15;[EPub Ahead of Print], H Hakariya, M Ohnishi, T Tanimoto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading